These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11796838)

  • 21. Cysteine proteinase inhibitor cystatin A in breast cancer.
    Kuopio T; Kankaanranta A; Jalava P; Kronqvist P; Kotkansalo T; Weber E; Collan Y
    Cancer Res; 1998 Feb; 58(3):432-6. PubMed ID: 9458085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
    Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein.
    Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
    Clin Cancer Res; 2005 May; 11(9):3257-64. PubMed ID: 15867221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success.
    Span PN; Lindberg RL; Manders P; Tjan-Heijnen VC; Heuvel JJ; Beex LV; Sweep CG
    J Pathol; 2004 Apr; 202(4):395-402. PubMed ID: 15095266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer.
    Aljada IS; Ramnath N; Donohue K; Harvey S; Brooks JJ; Wiseman SM; Khoury T; Loewen G; Slocum HK; Anderson TM; Bepler G; Tan D
    J Clin Oncol; 2004 Aug; 22(16):3218-29. PubMed ID: 15249585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix].
    Zhou CY; Yao JF; Chen XD
    Ai Zheng; 2002 Jul; 21(7):735-9. PubMed ID: 12479097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
    Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
    Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome.
    Mylona E; Magkou C; Giannopoulou I; Agrogiannis G; Markaki S; Keramopoulos A; Nakopoulou L
    Breast Cancer Res; 2006; 8(5):R57. PubMed ID: 17032447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin.
    Massi D; Franchi A; Ketabchi S; Paglierani M; Pimpinelli N; Santucci M
    Hum Pathol; 2003 Jan; 34(1):80-8. PubMed ID: 12605370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer.
    Sharma R; Chattopadhyay TK; Mathur M; Ralhan R
    Oncology; 2004; 67(3-4):300-9. PubMed ID: 15557792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expression of matrix metalloproteinase-2, 9 and it's tissue inhibitor-1, 2 in endometrial carcinoma].
    Guo W; Chen G; Zhu C; Wang H
    Zhonghua Fu Chan Ke Za Zhi; 2002 Oct; 37(10):604-7. PubMed ID: 12487935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
    Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
    Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
    Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
    Rudland PS; Platt-Higgins A; El-Tanani M; De Silva Rudland S; Barraclough R; Winstanley JH; Howitt R; West CR
    Cancer Res; 2002 Jun; 62(12):3417-27. PubMed ID: 12067984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status.
    Kuvaja P; Hulkkonen S; Pasanen I; Soini Y; Lehtonen S; Talvensaari-Mattila A; Pääkkö P; Kaakinen M; Autio-Harmainen H; Hurskainen T; Lehenkari P; Turpeenniemi-Hujanen T
    Exp Cell Res; 2012 Jun; 318(10):1094-103. PubMed ID: 22465225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
    Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
    Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.